

1 Progression and Resolution of SARS-CoV-2 Infection in Golden Syrian Hamsters

2
3 Kathleen R. Mulka¹, Sarah E. Beck^{1,2}, Clarisse V. Solis¹, Andrew L. Johanson¹,
4 Suzanne E. Queen¹, Megan E. McCarron¹, Morgan R. Richardson¹, Ruifeng Zhou⁴,
5 Paula Marinho⁴, Anne Jedlicka⁴, Selena Guerrero-Martin¹, Erin N. Shirk¹, Alicia
6 Braxton¹, Jacqueline Brockhurst¹, Patrick S. Creisher⁴, Santosh Dhakal⁴, Cory F.
7 Brayton¹, Rebecca T. Veenhuis¹, Kelly A. Metcalf Pate¹, Petros C. Karakousis⁶, Sabra
8 L. Klein⁴, Sanjay K. Jain⁵, Patrick M. Tarwater⁷, Andrew S. Pekosz^{1,4}, Jason S. Villano¹,
9 and Joseph L. Mankowski^{1,2,3} for the Johns Hopkins COVID-19 Hamster Study Group

10
11 ¹Department of Molecular and Comparative Pathobiology, The Johns Hopkins School of
12 Medicine, Baltimore, Maryland, USA

13 ²Department of Pathology, The Johns Hopkins School of Medicine, Baltimore,
14 Maryland, USA

15 ³Department of Neurology, The Johns Hopkins School of Medicine, Baltimore,
16 Maryland, USA

17 ⁴W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns
18 Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

19 ⁵Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore,
20 Maryland, USA

21 ⁶Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland,
22 USA

23 ⁷Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health,
24 Baltimore, Maryland, USA

25

26 To whom correspondence should be addressed: Joseph L. Mankowski,
27 jmankows@jhmi.edu

28

29 Current address for K. Metcalf Pate: Division of Comparative Medicine and Department
30 of Biological Engineering, Massachusetts Institute of Technology, Cambridge,
31 Massachusetts, USA

32

33

34 Running Head

35 Pathogenesis of SARS-CoV-2 Infection in Hamsters

36

37 **Grant numbers and sources of funding**

38 These studies were also supported through the generosity of the collective community
39 of donors to the Johns Hopkins University School of Medicine for COVID research
40 (JLM), NIH OD T32OD011089 (JLM), The Johns Hopkins Center of Excellence in
41 Influenza Research and Surveillance (HHSN272201400007C AP, SLK), the NIH/NCI
42 COVID-19 Serology Center of Excellence U54CA260492 (SLK), the NIH/ORWH/NIA
43 Specialized Center of Research Excellence in Sex Differences U54AG062333 (SLK),
44 R01AI153349 (SKJ), support from the Center for Infection and Inflammation Imaging
45 Research (Johns Hopkins University, SKJ).

46

47

48

49 **Abstract**

50 To catalyze SARS-CoV-2 research including development of novel interventive and
51 preventive strategies, we characterized progression of disease in depth in a robust
52 COVID-19 animal model. In this model, male and female golden Syrian hamsters were
53 inoculated intranasally with SARS-CoV-2 USA-WA1/2020. Groups of inoculated and
54 mock-inoculated uninfected control animals were euthanized at day 2, 4, 7, 14, and 28
55 days post-inoculation to track multiple clinical, pathology, virology, and immunology
56 outcomes. SARS-CoV-2-inoculated animals consistently lost body weight during the first
57 week of infection, had higher lung weights at terminal timepoints, and developed lung
58 consolidation per histopathology and quantitative image analysis measurements. High
59 levels of infectious virus and viral RNA were reliably present in the respiratory tract at
60 days 2 and 4 post-inoculation, corresponding with widespread necrosis and
61 inflammation. At day 7, when infectious virus was rare, interstitial and alveolar
62 macrophage infiltrates and marked reparative epithelial responses (type II hyperplasia)
63 dominated in the lung. These lesions resolved over time, with only residual epithelial
64 repair evident by day 28 post-inoculation. The use of quantitative approaches to
65 measure cellular and morphologic alterations in the lung provides valuable outcome
66 measures for developing therapeutic and preventive interventions for COVID-19 using
67 the hamster COVID-19 model.

68

69 **Introduction**

70 In December 2019, a novel beta coronavirus was isolated from patients that presented
71 with severe and ultimately fatal pneumonia in Wuhan, China¹. The virus was designated

72 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and rapidly spread
73 through human-to-human transmission, causing the current global pandemic of
74 Coronavirus Disease 2019 (COVID-19). As of June 2021, there have been over 168
75 million confirmed cases and over 3.5 million deaths globally attributed to SARS-CoV-2
76 infection².

77 While many organ systems can be affected by SARS-CoV-2 infection, pulmonary
78 disease has been most frequently associated with severe and fatal cases of COVID-
79 19³. The earliest stage of disease is characterized by edema and vascular damage
80 including endothelial cell degeneration and necrosis, with neutrophilic infiltration of
81 alveolar septa and capillaries (endothelialitis and capillaritis) and microthrombosis³⁻⁶.

82 This is followed by an exudative phase of diffuse alveolar damage (DAD), with fibrinous
83 edema in the alveolar spaces, increased numbers of macrophages and epithelial
84 multinucleated giant cells, hyaline membrane formation, and epithelial necrosis followed
85 by type 2 pneumocyte hyperplasia. Additionally, vascular changes occur, including
86 endothelial necrosis, hemorrhage, thrombosis of capillaries and small arteries, and
87 vasculitis^{5,7}. In turn, the organizing stage of DAD, and the final fibrotic stage of DAD
88 ensue which may include proliferation of myofibroblasts within the lung interstitium, and
89 deposition of collagen leading to fibrosis. Squamous metaplasia has also been
90 observed^{3,8}.

91

92 The emergent and widespread nature of this pandemic necessitated the rapid
93 development of multiple animal models and biologic systems to study various aspects of
94 pathogenesis, treatment, and prevention of disease. To date, reported animal models of

95 COVID-19 pathology include human ACE2 transgenic mice⁹⁻¹², golden Syrian
96 hamsters¹²⁻¹⁸, nonhuman primates^{19,20}, and ferrets^{21,22}; recent comprehensive reviews
97 of animal models of COVID-19 were provided by Zeiss et al., and Veenhuis and Zeiss,
98 2021^{23,24}. Each model species has advantages and limitations with respect to similarity
99 to disease in humans, expense, and practicality. The hamster model offers several
100 advantages over other animal models: it is a relatively small, immunocompetent animal
101 that is susceptible to infection with varied SARS-CoV-2 clinical isolates and readily
102 develops pulmonary disease. Specifically, hamsters consistently develop moderate to
103 severe bronchointerstitial pneumonia characterized by acute inflammation, edema, and
104 necrosis 2-4 days post SARS-CoV2 challenge, progressing to proliferative interstitial
105 pneumonia with type II pneumocyte hyperplasia by 7 days post-challenge. Pulmonary
106 lesions have been reported to resolve around 10-14 days post-inoculation with little to
107 no evidence of residual damage^{13-18,20,25}.

108
109 Although several studies have provided an overview of pulmonary pathology during
110 acute infection, comprehensive longitudinal assessments of pulmonary pathology are
111 lacking, including chronic time points. Likewise, there is a dearth of information available
112 integrating clinical, pathology, virology, and immunology findings or reporting systemic
113 pathologic findings associated with SARS-CoV-2 infection in hamsters. In this study, we
114 provide in-depth, longitudinal, pathological characterization of multisystemic disease
115 manifestation caused by SARS-CoV-2 infection in male and female golden Syrian
116 hamsters. Furthermore, we objectively measured tissue damage and inflammatory
117 responses by digital image analysis using an open-source platform, QuPath^{26,27}. Our

118 results show that inoculating hamsters intranasally with SARS-CoV-2 reliably induces
119 acute damage to the respiratory tract with initial viral replication followed by a
120 macrophage-dominant pulmonary immune response. In turn, a reparative phase follows
121 with abundant type II pneumocyte hyperplasia restoring the alveolar lining, mirroring
122 SARS-CoV-2 infection in humans.

123

124 **Materials and Methods**

125 **Animals**

126 7 to 8 week old male and female golden Syrian hamsters *Mesocricetus auratus*
127 (Envigo) were singly housed in the JHU CRB Animal Biosafety Level 3 (ABSL)-3 facility.
128 After acclimation (7 day minimum), hamsters were sedated intramuscularly with
129 xylazine and ketamine then inoculated intranasally with 10^5 TCID₅₀ of SARS-CoV-2
130 USA-WA1/2020, (BEI Resources NR#52281) diluted in 100uL DMEM; virus stocks.
131 Uninfected animals were mock-inoculated with 100 μ L of DMEM intranasally to serve as
132 controls. Groups of 12 animals (4 mock and 8 SARS-CoV-2 inoculated, equal numbers
133 of males and females) were euthanized at 2, 4, 7 and 14 days post inoculation (DPI). An
134 additional group of 4 mock (2 male and 2 female) and 19 SARS-CoV-2-inoculated
135 hamsters (10 male and 9 female) were euthanized at 28 DPI. Body weights were
136 measured daily until 10 DPI, then on 14, 21, and 28 DPI. Blood samples were collected
137 at 0, 7, 14, 21, and 28 DPI depending on group. Terminal blood samples obtained via
138 cardiac puncture were saved for serology, coagulation assays, FACS analysis,
139 hematology, and clinical chemistries. At study endpoints, animals were euthanized with
140 intraperitoneal sodium pentobarbital. A complete post-mortem examination with

141 comprehensive tissue harvest (flash frozen and 10% NBF immersion fixed samples)
142 was performed on all hamsters. ACUC statement. The animal procedures in this study were
143 in accordance with the principles set forth by the Institutional Animal Care and Use Committee
144 at Johns Hopkins University and the National Research Council's Guide for the Care and Use of
145 Laboratory Animals (8th edition)

146

147 SARS-CoV-2 measurements

148 Infectious virus titers in the respiratory tissue homogenates were determined by the
149 50% tissue culture infectious dose (TCID₅₀) assay²⁸. Briefly, tissue homogenates were
150 serially diluted 10-fold, transferred in sextuplicate into 96-well plates confluent with
151 Vero-E6-TMPRSS2 cells (obtained from the Japan Institute of Infectious Diseases),
152 incubated at 37°C for 4 days, and then stained with naphthol blue-black solution for
153 visualization. Infectious viral titers (TCID₅₀/mL) were determined by Reed and Muench
154 method. For detection of SARS-CoV-2 genome copies, RNA was extracted from lungs
155 using the Qiagen viral RNA extraction kit (Qiagen) and reverse transcriptase PCR
156 (RTqPCR) was performed as previously described²⁹. Viral data from a subset of these
157 animals has been included in a report on humoral responses in this model²⁸.

158

159 Postmortem examination

160 Standard necropsy procedures included gross examination of all major organs. After
161 obtaining organ weights, samples were either frozen or immersion fixed in 10% neutral-
162 buffered formalin. The lungs were weighed en bloc, and then the left lobe was removed
163 at the level of the left bronchus. Formalin was gently infused into the left bronchus to

164 inflate the left lobe, then the entire lobe was submerged in formalin. The right lung lobes
165 were divided into different frozen sample collection tubes for preparing tissue
166 homogenates and RNA extraction.

167

168 Histopathology analyses

169 After immersion fixation in 10% neutral-buffered formalin for 72 hours, tissues were
170 trimmed, processed, and embedded in paraffin. 5µm thick sections were mounted on
171 glass slides and stained with hematoxylin and eosin (H&E). Histopathological analysis
172 was performed independently by two veterinary pathologists (S.B. and K.M.) blinded to
173 animal identification and infection status. Tissues evaluated included nasal cavity,
174 trachea, lung (left lobe), esophagus, stomach, small intestine, cecum, large intestine,
175 brain, heart, kidney, liver, gallbladder, spleen, adrenal gland, reproductive organs,
176 urinary bladder, lymph nodes, salivary glands, bone, haired skin, skeletal muscle, bone
177 marrow, and decalcified cross sections of the head.

178

179 *In situ* hybridization and immunohistochemistry

180 *In situ* hybridization to detect SARS-CoV-2 RNA

181 *In situ* hybridization (ISH) was performed on 5µm-thick sections of formalin-fixed lung
182 mounted on charged glass slides using the Leica Bond RX automated system (Leica
183 Biosystems, Richmond, IL). Heat-induced epitope retrieval was conducted by heating
184 slides to 95°C for 15 minutes in EDTA-based ER2 buffer (Leica Biosystems, Richmond,
185 IL). The SARS-CoV-2 probe (cat. 848568, Advanced Cell Diagnostics, Newark, CA) was
186 used with the Leica RNAScope 2.5 LS Assay-RED kit and a hematoxylin counterstain

187 (Leica Biosystems, Richmond, IL). Slides were treated in protease (Advanced Cell
188 Diagnostics, Newark, CA) for 15 minutes and probes hybridized to RNA for 1 minute. An
189 RNAPol2 probe served as a hamster gene control to ensure ISH sensitivity; a probe for
190 the bacterial *dap2* gene was used as a negative control ISH probe.

191

192 Immunohistochemistry

193 10% NBF-fixed lung sections of SARS-CoV-2 infected and control animals were
194 immunostained with anti-Iba-1 antibody (1:2000; Wako; 019-19741 Richmond, VA),
195 anti-CD3 antibody (1:200; DAKO; Ref: A0452 Santa Clara, CA, or anti-pan-cytokeratin
196 antibody (1:1000; Santa Cruz; sc-8018 Dallas, TX). Heat-induced epitope retrieval was
197 conducted by heating slides to 95°C for 20 minutes in sodium citrate-based ER1 buffer
198 (Leica Biosystems, Richmond, IL) before immunostaining. Dual immunostaining for the
199 epithelial marker pan-cytokeratin and the macrophage marker Iba-1 was performed on
200 lung sections of SARS-CoV-2-infected animals. For epitope retrieval, slides were
201 heated to 100°C in sodium citrate-based ER1 buffer for 20 minutes (Leica Biosystems,
202 Richmond, IL). Slides were then stained with anti-Iba1 antibody (1:2000; Wako; 019-
203 19741 Richmond, VA) using the Bond Polymer Refine Red Kit (cat. DS9390 Leica
204 Biosystem, Richmond, IL). The slides were stained using a pan-cytokeratin antibody
205 (1:1000; Santa Cruz; Sc-8018; Dallas, TX) with the Bond Polymer Refine Kit (cat.
206 DS9800 Leica Biosystem, Richmond, IL). Immunostaining was performed using the
207 Bond RX automated system (Leica Biosystems, Richmond, IL). Positive immunostaining
208 was visualized using DAB and RED, and slides were counterstained with hematoxylin.

209

210 Digital Image Analysis

211 Whole slides containing sections of the entire left lung lobe cut through the long axis
212 were scanned at 20x magnification on the Zeiss Axio Scan.Z1 platform using automatic
213 tissue detection with manual verification. Lung sections were analyzed using QuPath v.
214 0.2.2 (complete code included in supplemental methods). To measure Iba-1 and CD3
215 immunostaining, the create thresholder function was applied to detect levels of DAB
216 above a threshold that was designated as positive within a given annotated area, or
217 region of interest (ROI). The percent positive ROI was calculated using positive area
218 quantitated by the thresholder divided by total area of the ROI. For SARS-CoV-2 ISH
219 quantitation, the train pixel classifier tool was used. Within an ROI, annotations were
220 created and designated as either positive or ignore, which allowed QuPath to correctly
221 identify areas of positive staining. Percent positive ROI was calculated using positive
222 area detected by the classifier divided by total area of the ROI.

223

224 To quantitate consolidation of 7 DPI lungs, the wand tool was used to outline each
225 scanned section of lung, creating an annotation. Superpixels were generated using the
226 DoG superpixel segmentation function in QuPath. These detections were then selected,
227 and intensity features were added. Next, areas within the ROI were annotated using
228 multiple slides of infected and control animals that were designated as “Consolidation”,
229 “Non-consolidated”, “Atelectasis”, or “Ignore”. This allowed the classifier to successfully
230 detect areas of affected tissue, while ignoring areas that were unaffected, densely
231 stained due to normal tissue architecture, or collapsed due to variable formalin infusion
232 of the lungs. Percent consolidation was calculated using the number of superpixels

233 identified as consolidated divided by the total number of superpixels detected for a
234 given slide.

235

236 Flow Cytometry

237 Freshly collected whole blood in EDTA was stained for FACS analysis with the limited
238 antibodies available that cross-react in the hamster model at the initiation of the study.

239 Cell surface markers for CD4 (anti-mouse, clone GK1.5, Biolegend, San Diego, CA),

240 CD8 (anti-rat, clone 341, BD biosciences, San Jose, CA), MHC II (anti-mouse, clone 14-

241 4-4S, BD Biosciences), and a Live/Dead discriminator (Fixable Near-IR Dead Cell Stain

242 Kit, ThermoFisher, Waltham, MA) consistently stained populations of lymphocytes or

243 monocytes allowing for a limited understanding of the proportion of these cell types.

244 Whole-blood samples were stained with pre-titered amounts of the indicated

245 monoclonal antibodies using 50ul of whole blood at room temperature for 20 min. Whole

246 blood samples were then lysed and fixed in 2 ml of FACS Lysing Solution (BD

247 Biosciences, San Jose, CA) for 10 min at room temperature. Samples were collected in

248 a centrifuge at 400 x g for 5min, washed in 2 ml of 1x phosphate-buffered saline (PBS),

249 and then resuspended in 0.5 ml of PBS for analysis. Flow cytometry was performed on

250 a BD LSRFortessa (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo

251 10.0.8 software (FlowJo, LLC, Ashland, OR). Whole blood was first gated on size and

252 complexity using FSC-A and SSC-A to remove debris, followed by using FSC-H and

253 FSC-A and SSC-H and SSC-A measurements to remove doublet populations. Single

254 cells were then gated into lymphocyte or monocyte populations based on size and

255 complexity profiles, and then gated to include only live cells using a Live/Dead viability

256 stain. Live lymphocyte-sized cells were gated as MHC II negative/dim (T cells) or MHC
257 II+ (B cells). The MHC II-negative cells were further gated on their expression of CD4 or
258 CD8. Populations of MHC II+ B cells, CD4+ lymphocytes, and CD8+ lymphocytes were
259 calculated as a proportion of total viable lymphocytes. Live monocyte-sized cells were
260 further gated as MHC II+.

261

262 Statistical analysis

263 Statistical analyses were performed using GraphPad Prism version 7.04. One-way
264 analysis of variance (ANOVA) was used to detect significant differences between
265 groups of animals sampled at different time points post-inoculation. The two-sample t-
266 test was used to evaluate differences between two groups. Infectious virus titers and
267 viral RNA copies were log transformed and compared using two-way ANOVA with
268 mixed-effects analysis followed by Bonferroni's multiple comparison test.

269

270 Results

271 Clinical Outcomes

272 The most robust finding following SARS-CoV-2 inoculation was decreased body weight
273 (**Fig 1A**). Animals inoculated with SARS-CoV-2 progressively lost body weight in the
274 first week of infection until the 6 DPI nadir (-13.8% decline in group mean body weight
275 from baseline; 19.3 % lower than control animal group mean at 6 DPI, $P < 0.001$) before
276 gradually rebounding over the course of the following 3 weeks. At day 28 DPI, control
277 and infected group body weights were not significantly different ($P=0.095$). Sex

278 differences in body mass loss have been documented in hamsters infected with SARS-
279 CoV-2, and those differences were explored previously²⁸.

280 SARS-CoV-2-inoculated hamsters did not consistently develop clinical signs of
281 respiratory disease; only mild nasal discharge or slight increased respiratory effort was
282 observed intermittently in very few animals.

283 **SARS-CoV-2 infectious virus and viral RNA measurements in the respiratory tract**

284 Peak infectious viral titers in the nasal turbinates, trachea, and lungs were present at 2
285 DPI, then decreased at 4 DPI (Fig. 2). The highest levels of infectious SARS-CoV-2
286 were found in nasal turbinates at 2 DPI (5.0×10^7 TCID₅₀/mL); lung levels were highest at
287 2 DPI (7.33×10^6 TCID₅₀). While infectious virus was cleared from the respiratory tract
288 of most of the hamsters by 7 DPI, infectious virus was detected in the lungs of a single
289 animal. No sex differences in viral load were detected in infected hamsters²⁸.

290

291 **Gross Pathology**

292 On gross necropsy examination, lungs from both infected and control animals were
293 indistinguishable, with variably mottled red to brown coloration randomly distributed in
294 all lung lobes, suggesting that this change was due to perimortem procedures and not a
295 reliable indicator of pathology related to SARS-CoV-2 infection. Two animals had
296 adhesions between the lung lobes and the diaphragm; both were infected animals
297 euthanized 7 DPI. Compared to uninfected control animals, average post-mortem lung
298 weights were 50% higher in infected animals at 4 DPI and 105% higher at 7 DPI (**Fig**
299 **1B**; $P = 0.014$; $P < 0.0001$, respectively, 2-way ANOVA multiple comparisons). All other
300 tissues were unremarkable in both control and SARS-CoV-2-infected animals.

301

302 **Longitudinal Progression of Lesions in the Respiratory System**

303 *2 DPI:*

304 The nasal cavity contained eosinophilic proteinaceous exudate with abundant
305 degenerate neutrophils in all infected animals (8/8) and no uninfected animals (0/4). In 7
306 of 8 infected animals, olfactory epithelium damage ranged from degeneration to
307 necrosis with erosion accompanied by infiltrating neutrophils classified as rhinitis. The
308 tracheal submucosa contained mild infiltrates of mononuclear cells in 3/6 infected
309 animals with tissue available for evaluation, (tissue not present in 2/8 infected animals),
310 and no uninfected animals. In infected animals, within the lungs, (Fig 3, 2 DPI) the
311 following changes were observed: minimal to moderate suppurative bronchitis and
312 bronchiolitis (8/8), bronchial and bronchiolar intraluminal neutrophilic necrotic cellular
313 debris (7/8), bronchial epithelial syncytia (2/8), alveolar septa expanded by inflammatory
314 cells and eosinophilic proteinaceous material (4/8), intra-alveolar macrophages,
315 neutrophils, necrotic cellular debris, and fibrinous exudate (6/8). Vascular changes in
316 lungs included: reactive vascular endothelium within small to medium arteries (4/8),
317 perivascular edema, and leukocytes infiltrating through the vascular walls (2/8).
318 The lungs of the uninfected control animals had no significant findings. Intra-alveolar
319 hemorrhage was observed intermittently in both uninfected and infected groups at all
320 time points attributed to tissue collection artifact.

321

322 *4 DPI:*

323 The nasal cavity still contained eosinophilic proteinaceous exudate mixed with abundant
324 degenerate neutrophils in all infected animals and none of the uninfected animals.
325 Olfactory epithelium was multifocally eroded with degenerate and necrotic epithelium;
326 inflammatory cells consisted of predominantly neutrophils infiltrating into the mucosa.
327 The tracheal submucosa only contained mild scattered infiltrates of mononuclear cells in
328 one infected animal.

329

330 Lung changes within the medium to large airways in infected animals (Fig. 3, 4 DPI)
331 included minimal to moderate suppurative bronchitis and bronchiolitis (8/8), bronchial
332 and bronchiolar intraluminal neutrophilic necrotic cellular debris (8/8), bronchial
333 epithelial syncytia (8/8), and bronchial epithelial hyperplasia (8/8). Inflammatory
334 changes extended into the alveolar parenchyma, and included increased numbers of
335 intra-alveolar macrophages, neutrophils, necrotic cellular debris, and eosinophilic
336 fibrinous exudate (8/8), fibrin lining alveoli (7/8), and alveolar septal necrosis (2/8).
337 Additionally, small foci of type II pneumocyte hyperplasia were present with large,
338 atypical cells (8/8). Atypical cells were characterized by large, 15-20- μ m diameter
339 nuclei, with lacy chromatin and 1-3 prominent nucleoli, and moderate to large amounts
340 of basophilic vacuolated cytoplasm. Vascular changes included reactive vascular
341 endothelium within small to medium arteries (8/8), perivascular lymphocytic aggregates
342 (8/8), and mild to severe vasculitis (7/8).

343

344 *7 DPI:*

345 The nasal cavity contained mild to moderate amounts of eosinophilic proteinaceous
346 exudate with some degenerate neutrophils in 8/8 infected animals and 0/4 uninfected

347 animals. At this stage, the changes in the lungs reflect a culmination of the inflammatory
348 and reparative processes. All infected animals (8/8) developed large areas of pulmonary
349 consolidation encompassing most of the lung (see Fig 3, 7 DPI) characterized by type
350 II pneumocyte hyperplasia and bronchial epithelial hyperplasia that was frequently
351 atypical, with large nuclei in variably sized cells, and frequent multinucleated cells and
352 mitotic figures, resulting in massive thickening of the alveolar septa. Remaining alveolar
353 air spaces in these affected areas of lung contained large numbers of macrophages
354 with fewer degenerate neutrophils and multifocal necrotic debris. Aggregates of
355 lymphocytes and plasma cells occasionally surrounded (8/8) and infiltrated (2/8)
356 medium sized pulmonary arteries.

357

358 *14 DPI:*

359 The nasal cavity and trachea morphology were unremarkable in all infected (8/8) and
360 control (4/4) animals. In infected animals, within the lungs (Figure 2, 14 DPI) there were
361 scattered tufts of cuboidal, type II pneumocyte hyperplasia (8/8), rare randomly
362 distributed clusters of macrophages that occasionally admixed with lymphocytes and
363 neutrophils (8/8), small perivascular aggregates of lymphocytes (5/8), and multifocal
364 small clusters of pigmented macrophages (4/8).

365

366 *28 DPI:*

367 The nasal cavity and trachea morphology were unremarkable in all infected (8/8) and
368 control (4/4) animals. In infected animals, the lungs (Fig. 2, 28 DPI) contained multifocal
369 residual areas of cuboidal, typical type II pneumocyte hyperplasia (8/8) often centered

370 on terminal bronchioles, small clusters of pigmented macrophages (6/8), and rare
371 aggregates of perivascular lymphocytes with pigmented macrophages (2/8). SARS-
372 CoV-2-infected hamsters could be distinguished from uninfected animals by the
373 presence of persistent type II pneumocyte hyperplasia in the infected animals. In
374 contrast, lung inflammation had resolved, and fibrosis had not developed.

375

376 **Tracking SARS-CoV-2 RNA by *in situ* hybridization**

377 RNAScope *in situ* hybridization was used to map distribution and amount of viral RNA in
378 the lungs of infected animals throughout infection. Viral RNA expression was
379 quantitated using QuPath pixel classification. Expression of viral RNA was significantly
380 different over time in infected animals (one-way ANOVA, $p < 0.0001$): 2 DPI lungs
381 demonstrated the highest expression in alveolar epithelial cells, bronchiolar and
382 bronchial epithelial cells, and alveolar macrophages (Figure 4). At 4 DPI, lung
383 expression was decreased compared to 2 DPI, with positive staining for viral RNA
384 largely restricted to the alveolar epithelial cells and alveolar macrophages in lung. At 7
385 DPI, lungs were largely negative; only one animal had multifocal low-level staining for
386 viral RNA within scattered alveolar epithelial cells. In addition to lung, scattered positive
387 staining for viral RNA was found within tracheobronchial lymph nodes and tracheal
388 epithelium at 2 DPI (7/7 animals with tissue present), and less frequently at 4 DPI (2/5
389 animals with tissue present). Viral RNA was detected by qRT-PCR for up to 28 DPI in
390 SARS-CoV-2-infected hamsters (Figure 6), suggesting that this may be the most
391 sensitive method for viral detection, though not indicative of infectivity.

392

393 **Immunophenotypic Characterization of Lung Inflammation**

394 To establish the immunophenotype and progression of inflammatory cell infiltrates in the
395 lung, lung sections from mock-inoculated and SARS-CoV 2-infected animals were
396 evaluated for expression of the macrophage marker Iba-1 and the T-cell marker CD3 at
397 2, 4, 7, and 14 DPI. Following immunostaining, QuPath was used to quantitate percent
398 positive ROI in whole slide scanned images of the left lung lobe, the largest hamster
399 lung lobe. Iba-1 expression was significantly different in infected animals versus
400 uninfected animals over time (one-way ANOVA, $p < 0.0001$). Specifically, Iba-1
401 immunostaining was higher in infected animals compared with uninfected control
402 animals at 2, 4, 7, and 14 DPI (t-tests, $p < 0.001$, $p < 0.001$, $P < 0.0001$, $P = 0.04$,
403 respectively).

404

405 CD3 expression reflecting T-cell responses was more variable than Iba-1 expression.
406 CD3 expression in infected animals was different over time (one-way ANOVA,
407 $p < 0.0001$). CD3 expression was significantly greater in infected animals compared with
408 uninfected control animals at 4 and 7 DPI (t tests, $p < 0.0001$, $p = 0.023$, respectively).
409 Expression of both Iba-1 and CD3 increased until 7 DPI, and then decreased at 14 DPI
410 (Figure 4) however IBA-1 expression was much more abundant than CD3, indicating
411 that macrophages comprised a greater portion of the inflammatory response in this
412 model, consistent with previous reports¹⁷. Many of the atypical and multinucleated cells
413 in the day 4 and day 7 animals were immunonegative for Iba-1 expression.
414 Immunostaining for pancytokeratin revealed that numerous atypical and multinucleated
415 cells were immunopositive, indicating that these cells were epithelial, consistent with

416 proliferative type II pneumocytes contributing to alveolar repair (Figure 5). Double
417 immunostaining demonstrated that both macrophages and proliferative epithelial cells
418 were present within the densely cellular areas of the lungs of 7 DPI animals, confirming
419 that inflammatory and reparative responses were contributing to the vast areas of
420 consolidation at this time point.

421

422 **Quantitation of Lung Consolidation at 7 DPI**

423 We used QuPath for digital image analysis to quantitate the percentage of lung that was
424 affected with inflammation and reparative processes in SARS-CoV2-infected animals.
425 The goal of this consolidation scoring approach was to encompass inflammatory cells
426 (macrophages, neutrophils, and scattered lymphocytes), type II pneumocyte
427 hyperplasia, necrotic cellular debris, and proteinaceous exudate while excluding
428 artefactual collapsed or poorly insufflated regions (atelectasis). Because atelectatic
429 areas in which alveolar septa are collapsed are common in postmortem lung examples,
430 there was a baseline level of detection above zero in control animals. When comparing
431 the percentage of consolidation in infected animals to the baseline level in control
432 animals, day 7 animals had a significant increase in fold change. Infected animals at 7
433 DPI had a mean value of 2.978-fold change above baseline ($P= 0.02$, Tukey's multiple
434 comparisons test). The highest percentage of affected lung was 59% and occurred in a
435 7 DPI animal. Consolidation scores were highly correlated with IBA-1 quantitation by
436 digital image analysis (Fig 8b; Pearson's $r = 0.84$; $P<0.0001$).

437

438 **Flow cytometry to detect alterations in circulating cells**

439 Fold change, relative to mock-infected hamsters at each time point, was used to assess
440 changes in the proportions of T-lymphocyte populations circulating in blood. A
441 significant early decrease in the proportion of CD8+ lymphocytes at 2 DPI was observed
442 (Fig. 8A, $P < 0.001$). No significant changes were observed in CD4+ lymphocytes (Fig.
443 8B, $P = 0.06$), however, the two 2 animals with the largest decrease in CD8+
444 lymphocytes also had a detectable decrease in CD4+ lymphocytes. No changes were
445 observed in either B cells or monocyte-sized MHCII+ cells in any animals (data not
446 shown).

447

448 **Histopathology of Organ Systems**

449 Minimal to mild multifocal hepatitis was observed in numerous animals. In some animals
450 this was associated with minimal hepatocellular necrosis with few neutrophils, in others
451 it was primarily lymphocytic. This was considered a background lesion as hepatitis was
452 seen in control animals as well as infected animals. The bone marrow in all animals was
453 densely cellular, with abundant myeloid cells including numerous band cells, as well as
454 erythroid and megakaryocyte lineages. The spleen in all animals was comprised of
455 predominantly red pulp, with no obvious signs of lymphoid depletion nor lymphoid
456 hyperplasia. Abdominal lymph nodes occasionally contained germinal centers in control
457 and infected animals. Incidental findings included rare protozoa associated with
458 superficial gastric mucosa (12/48), morphologically suggestive of *Cryptosporidium* spp,
459 with infrequent and mild hyperplasia of the affected gastric mucosa. No significant
460 changes were noted within the remaining gastrointestinal tract, including the oral cavity,
461 esophagus, small intestine, cecum, and colon. Kidneys in animals across all groups

462 (29/45) had minimal protein and mineral within the tubules. Adrenal glands within
463 hamsters of all groups had variable numbers of pigmented cells within the cortex, which
464 has been reported to be a change in aged hamsters³⁰. Other organs that were
465 examined without significant changes on histopathology included: brain, heart,
466 gallbladder, male and female reproductive organs, urinary bladder, salivary glands,
467 bone, haired skin, skeletal muscle, and decalcified cross sections of the head.

468

469 **Discussion**

470 In this study, we conducted a longitudinal, in-depth comprehensive histopathological
471 analysis of all tissues and organ systems within male and female golden Syrian
472 hamsters inoculated intranasally with SARS-CoV-2, spanning 2 to 28 days post-
473 inoculation. Additionally, we characterized the immunophenotype of the inflammatory
474 infiltrates within the lungs across all stages of disease and assessed viral load within the
475 lungs via *in situ* hybridization, virus titration, and qRT-PCR for viral RNA. We quantified
476 these morphologic findings using QuPath, an open-source digital image analysis
477 platform applied to analyze an entire lung lobe imaged via whole slide scanning. This
478 objective approach provided robust outcome measures for IHC, ISH, and consolidation,
479 enhancing rigor of this COVID-19 model.

480

481 The main lesion type within the lungs was proliferative bronchointerstitial pneumonia,
482 which started as acute necrosis of alveolar septa and airway epithelium coincident with
483 SARS-CoV-2 replication. Cellular immune responses were first dominated by recruited
484 neutrophils but switched to a macrophage-dominant phenotype accompanied by a

485 robust atypical type II pneumocyte reparative response beginning by day 4 and peaking
486 at day 7 post-inoculation, resembling other reports of disease timing in this animal
487 model^{13–18}. Pulmonary pathology findings closely emulated changes reported in
488 humans which include diffuse alveolar damage, intra-alveolar macrophage infiltration,
489 and type II pneumocyte hyperplasia³¹. Atypical proliferation of type II pneumocytes in
490 the hamster model during the reparative phase of disease is inconsistently reported but
491 was a very consistent and prominent finding in this study¹⁴. The striking proliferation
492 was more robust than what has been reported in humans with frequent anisocytosis and
493 anisokaryosis and numerous mitotic figures. Type II pneumocyte hyperplasia in
494 hamsters has been reported in other experimentally induced respiratory viral
495 infections^{32,33}, but is not usually this florid. Hamsters were evaluated from initial stages
496 of infection at progressive time points, whereas reports of human COVID-19 lung
497 pathology are cross-sectional, typically at autopsy representing the most severe
498 disease, the timing of lung sampling may explain this disparity.

499
500 Vascular changes are consistently described in human SARS-CoV-2 infection and are
501 thought to be a key factor in the pathogenesis of severely affected individuals^{4,31}. Within
502 the lungs, vascular changes in humans include endothelial damage, thrombosis,
503 microangiopathy, congestion, and angiogenesis⁴. In this study, within the pulmonary
504 vasculature, there was prominent endothelial hypertrophy in days 2-7, as well as overt
505 vasculitis in small and medium-sized arteries predominantly at day 4. Further
506 exploration and characterization of these changes in future studies is warranted given
507 the importance that these factors may play in human disease. Interstitial fibrosis is a

508 chronic sequela to SARS-CoV-2 infection in some individuals^{3,31}. Interestingly, while
509 interstitial fibrosis was not observed in this study, there was residual type II pneumocyte
510 hyperplasia at day 14 and 28 frequently present adjacent to terminal bronchioles, which
511 has not been reported in COVID-19 animal models or in human COVID-19 cases likely
512 because these changes develop during the reparative stage time points when post-
513 mortem samples are not typically available.

514

515 In this model, a significant decrease in the proportion of CD8+ lymphocytes in peripheral
516 blood of infected hamsters was detected at day 2 DPI. Further investigation is
517 warranted to characterize this change to determine if this is representative of a CD8-
518 dominant lymphopenia, as this could have important implications for pathogenesis and
519 may be representative of human disease^{24,34–37}. In human COVID-19 patients, CD8-
520 dominant lymphopenia has been consistently documented and critical patients have
521 more severe lymphopenia than individuals with mild cases^{35,37,38}. The mechanisms
522 underlying this change are unclear. In this study we did not observe destructive
523 changes in the thymus, spleen, lymph nodes or gut-associated lymphoid tissue
524 suggestive of lymphoid depletion.

525

526 Overall, hamsters developed consistent pulmonary disease associated with SARS-CoV-
527 2 infection progressing through distinct stages: acute viral replication and cell necrosis
528 accompanied by infiltrating neutrophils, a transition to macrophage-dominant
529 inflammation with control of viral replication and robust reparative epithelial responses
530 when lung consolidation were most severe 7 DPI, and resolution of inflammation with

531 residual evidence of epithelial repair still evident 28 DPI with SARS-CoV-2. Hamsters
532 are susceptible to infection with an intact immune system, in contrast to mouse model
533 systems in which the mouse or virus needs to be altered in order to study this pathogen
534 and disease. Hamsters also have the advantage of being a small animal model, which
535 are less expensive and easier to maintain than larger animals such as nonhuman
536 primates. The consistency of disease in this model further emphasizes the need to
537 develop additional antibodies and reagents to characterize immunopathologic changes.

538

539 This study provides detailed and objectively quantified longitudinal histopathological
540 analysis of the respiratory system, and describes associated changes observed in all
541 tissues and organ systems. These comprehensive and integrated findings on disease
542 progression and resolution serve as a baseline of SARS-CoV-2 infection outcome
543 measures in this model and will be valuable for determining the efficacy of therapeutic
544 and preventive interventions for COVID-19.

545

546 Acknowledgements

547 Additional Johns Hopkins COVID-19 Hamster Study Group members include: Michael
548 J. Betenbaugh, Bess Carlson, Natalie Castell, Jennie Ruelas Castillo, Kelly Flavahan,
549 Eric K. Hutchinson, Kirsten Littlefield, Monika M. Looney, Maggie Lowman, Natalia
550 Majewski, Amanda Maxwell, Filipa Mota, Alice L. Mueller, Alvaro A. Ordonez, Lisa
551 Pieterse, Darla Quijada, Camilo A. Ruiz-Bedoya, Mitchel Stover, Rachel Vistein,
552 Melissa Wood and Cynthia A. Zahnow.

553

554 AP would like to dedicate this manuscript to the memory of R. Mark Buller, whose
555 collaborations on the golden Syrian hamster model for SARS-CoV infection formed the
556 basis for this study.

557

558 References

- 559 1. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, Jiang Y-Z, Xiong Y, Li Y-J,
560 Li X-W, Li H, Fan G-H, Gu X-Y, Xiao Y, Gao H, Xu J-Y, Yang F, Wang X-M, Wu C,
561 Chen L, Liu Y-W, Liu B, Yang J, Wang X-R, Dong J, Li L, Huang C-L, Zhao J-P,
562 Hu Y, Cheng Z-S, Liu L-L, Qian Z-H, Qin C, Jin Q, Cao B, Wang J-W: Identification
563 of a novel coronavirus causing severe pneumonia in human: a descriptive study.
564 *Chin Med J* 2020, 133:1015–1024.
- 565 2. World Health Organization: Coronavirus Disease (Covid-19) Pandemic [Internet].
566 2020 [cited 2021 Feb 17],. Available from:
567 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- 568 3. Bösmüller H, Matter M, Fend F, Tzankov A: The pulmonary pathology of COVID-
569 19. *Virchows Archiv* 2021, .
- 570 4. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F,
571 Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D:
572 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N*
573 *Engl J Med* 2020, 383:120–128.
- 574 5. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S,
575 Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz
576 KD, Tzankov A: Postmortem examination of COVID-19 patients reveals diffuse
577 alveolar damage with severe capillary congestion and variegated findings in lungs
578 and other organs suggesting vascular dysfunction. *Histopathology* 2020, 77:198–
579 209.
- 580 6. Bösmüller H, Traxler S, Bitzer M, Häberle H, Raiser W, Nann D, Frauenfeld L,
581 Vogelsberg A, Klingel K, Fend F: The evolution of pulmonary pathology in fatal
582 COVID-19 disease: an autopsy study with clinical correlation. *Virchows Arch* 2020,
583 477:349–357.
- 584 7. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K,
585 Bargfrieder U, Trauner M: Pulmonary Arterial Thrombosis in COVID-19 With Fatal
586 Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case
587 Series. *Ann Intern Med* 2020, 173:350–361.
- 588 8. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Rech R,
589 Colombo R, Antinori S, Corbellino M, Galli M, Catena E, Tosoni A, Gianatti A,
590 Nebuloni M: Pulmonary post-mortem findings in a series of COVID-19 cases from
591 northern Italy: a two-centre descriptive study. *Lancet Infect Dis* 2020, 20:1135–
592 1140.
- 593 9. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE,
594 Earnest JT, Keeler SP, Ritter JH, Kang L-I, Dort S, Robichaud A, Head R,
595 Holtzman MJ, Diamond MS: SARS-CoV-2 infection of human ACE2-transgenic

- 596 mice causes severe lung inflammation and impaired function. *Nat Immunol* 2020,
597 21:1327–1335.
- 598 10. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE,
599 Earnest JT, Keeler SP, Ritter JH, Kang L-I, Dort S, Robichaud A, Head R,
600 Holtzman MJ, Diamond MS: SARS-CoV-2 infection in the lungs of human ACE2
601 transgenic mice causes severe inflammation, immune cell infiltration, and
602 compromised respiratory function. *BioRxiv* 2020, .
- 603 11. Sun S-H, Chen Q, Gu H-J, Yang G, Wang Y-X, Huang X-Y, Liu S-S, Zhang N-N, Li
604 X-F, Xiong R, Guo Y, Deng Y-Q, Huang W-J, Liu Q, Liu Q-M, Shen Y-L, Zhou Y,
605 Yang X, Zhao T-Y, Fan C-F, Zhou Y-S, Qin C-F, Wang Y-C: A Mouse Model of
606 SARS-CoV-2 Infection and Pathogenesis. *Cell Host Microbe* 2020, 28:124–
607 133.e4.
- 608 12. Abdel-Moneim AS, Abdelwhab EM: Evidence for SARS-CoV-2 Infection of Animal
609 Hosts. *Pathogens* 2020, 9.
- 610 13. Sia SF, Yan L-M, Chin AWH, Fung K, Choy K-T, Wong AYL, Kaewpreedee P,
611 Perera RAPM, Poon LLM, Nicholls JM, Peiris M, Yen H-L: Pathogenesis and
612 transmission of SARS-CoV-2 in golden hamsters. *Nature* 2020, 583:834–838.
- 613 14. Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC-Y, Chan W-M,
614 Fan Z, Tsoi H-W, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai J-P, Kok K-
615 H, Chu H, Chan K-H, Sridhar S, Chen Z, Chen H, To KK-W, Yuen K-Y: Simulation
616 of the Clinical and Pathological Manifestations of Coronavirus Disease 2019
617 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease
618 Pathogenesis and Transmissibility. *Clin Infect Dis* 2020, 71:2428–2446.
- 619 15. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N,
620 Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M,
621 Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H,
622 Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N,
623 Ohmagari N, Hattori S-I, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y:
624 Syrian hamsters as a small animal model for SARS-CoV-2 infection and
625 countermeasure development. *Proc Natl Acad Sci USA* 2020, 117:16587–16595.
- 626 16. Osterrieder N, Bertzbach LD, Dietert K, Abdelgawad A, Vladimirova D, Kunec D,
627 Hoffmann D, Beer M, Gruber AD, Trimpert J: Age-dependent progression of
628 SARS-CoV-2 infection in Syrian hamsters. *BioRxiv* 2020, .
- 629 17. Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J,
630 Chan CN, Bondoc S, Starke CE, Nekorchuk M, Busman-Sahay K, Piedra-Mora C,
631 Wrijil LM, Ducat S, Custers J, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser
632 BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Lin Z,
633 Mahrokhian SH, Nampanya F, Nityanandam R, Pessaint L, Porto M, Ali V,
634 Benetiene D, Tevi K, Andersen H, Lewis MG, Schmidt AG, Lauffenburger DA,

- 635 Alter G, Estes JD, Schuitemaker H, Zahn R, Barouch DH: Ad26 vaccine protects
636 against SARS-CoV-2 severe clinical disease in hamsters. *Nat Med* 2020,
637 26:1694–1700.
- 638 18. Kreye J, Reincke SM, Kornau H-C, Sánchez-Sendin E, Corman VM, Liu H, Yuan
639 M, Wu NC, Zhu X, Lee C-CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von
640 Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber
641 AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriener K, Hocke AC,
642 Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D,
643 Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C,
644 Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H: A Therapeutic Non-
645 self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19
646 Hamster Model. *Cell* 2020, 183:1058–1069.e19.
- 647 19. Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L,
648 Schulz J, Meade-White K, Okumura A, Callison J, Brumbaugh B, Avanzato VA,
649 Rosenke R, Hanley PW, Saturday G, Scott D, Fischer ER, de Wit E: Respiratory
650 disease in rhesus macaques inoculated with SARS-CoV-2. *Nature* 2020, 585:268–
651 272.
- 652 20. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, Ni M, Wei Y,
653 Mohammadi K, Musser B, Atwal GS, Oyejide A, Goez-Gazi Y, Dutton J,
654 Clemmons E, Staples HM, Bartley C, Klaffke B, Alfson K, Gazi M, Gonzalez O,
655 Dick E, Carrion R, Pessaint L, Porto M, Cook A, Brown R, Ali V, Greenhouse J,
656 Taylor T, Andersen H, Lewis MG, Stahl N, Murphy AJ, Yancopoulos GD,
657 Kyratsous CA: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in
658 rhesus macaques and hamsters. *Science* 2020, 370:1110–1115.
- 659 21. Kim Y-I, Kim S-G, Kim S-M, Kim E-H, Park S-J, Yu K-M, Chang J-H, Kim EJ, Lee
660 S, Casel MAB, Um J, Song M-S, Jeong HW, Lai VD, Kim Y, Chin BS, Park J-S,
661 Chung K-H, Foo S-S, Poo H, Mo I-P, Lee O-J, Webby RJ, Jung JU, Choi YK:
662 Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host Microbe*
663 2020, 27:704–709.e2.
- 664 22. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell P-S, Riveros-Balta AX,
665 Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I,
666 Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D,
667 Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL,
668 Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I,
669 Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu W-C, Maisonnasse P, McElroy
670 AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B,
671 Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ,
672 Tseng C-T, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts
673 J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-Restrepo
674 AM, Barouch DH: Animal models for COVID-19. *Nature* 2020, 586:509–515.

- 675 23. Zeiss CJ, Compton S, Veenhuis RT: Animal Models of COVID-19. I. Comparative
676 Virology and Disease Pathogenesis. *ILAR J* 2021, .
- 677 24. Veenhuis RT, Zeiss CJ: Animal Models of COVID-19 II. Comparative Immunology.
678 *ILAR J* 2021, .
- 679 25. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, Limbo O, Smith C,
680 Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren
681 M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M,
682 Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B,
683 Landais E, Sok D, Jardine JG, Burton DR: Isolation of potent SARS-CoV-2
684 neutralizing antibodies and protection from disease in a small animal model.
685 *Science* 2020, 369:956–963.
- 686 26. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD,
687 McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M,
688 Hamilton PW: QuPath: Open source software for digital pathology image analysis.
689 *Sci Rep* 2017, 7:16878.
- 690 27. Morriss NJ, Conley GM, Ospina SM, Meehan Iii WP, Qiu J, Mannix R: Automated
691 quantification of immunohistochemical staining of large animal brain tissue using
692 qupath software. *Neuroscience* 2020, 429:235–244.
- 693 28. Dhakal S, Ruiz-Bedoya CA, Zhou R, Creisher P, Villano J, Littlefield K, Castillo J,
694 Marinho P, Jedlicka A, Ordonez A, Majewska N, Betenbaugh M, Flavahan K,
695 Mueller A, Looney M, Quijada D, Mota F, Beck SE, Brockhurst JK, Braxton A,
696 Castell N, D’Alessio F, Metcalf Pate KA, Karakousis PC, Mankowski JL, Pekosz A,
697 Jain SK, Klein SL: Sex differences in lung imaging and SARS-CoV-2 antibody
698 responses in a COVID-19 golden Syrian hamster model. *BioRxiv* 2021, .
- 699 29. Gniazdowski V, Morris CP, Wohl S, Mehoke T, Ramakrishnan S, Thielen P, Powell
700 H, Smith B, Armstrong DT, Herrera M, Reifsnnyder C, Sevdali M, Carroll KC,
701 Pekosz A, Mostafa HH: Repeat COVID-19 Molecular Testing: Correlation of
702 SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds. *Clin Infect Dis*
703 2020, .
- 704 30. Meyers MW, Charipper HA: A histological and cytological study of the adrenal
705 gland of the golden hamster (*Cricetus auratus*) in relation to age. *Anat Rec* 1956,
706 124:1–25.
- 707 31. Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J: A
708 systematic review of pathological findings in COVID-19: a pathophysiological
709 timeline and possible mechanisms of disease progression. *Mod Pathol* 2020,
710 33:2128–2138.
- 711 32. Baseler L, de Wit E, Scott DP, Munster VJ, Feldmann H: Syrian hamsters
712 (*Mesocricetus auratus*) oronasally inoculated with a Nipah virus isolate from

- 713 Bangladesh or Malaysia develop similar respiratory tract lesions. *Vet Pathol* 2015,
714 52:38–45.
- 715 33. Prescott J, Safronetz D, Haddock E, Robertson S, Scott D, Feldmann H: The
716 adaptive immune response does not influence hantavirus disease or persistence in
717 the Syrian hamster. *Immunology* 2013, 140:168–178.
- 718 34. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L,
719 Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu
720 L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B,
721 Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li
722 L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X: Longitudinal
723 characteristics of lymphocyte responses and cytokine profiles in the peripheral
724 blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020, 55:102763.
- 725 35. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y:
726 Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19
727 Pneumonia. *J Infect Dis* 2020, 221:1762–1769.
- 728 36. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R, Song M,
729 Wang L, Zhang W, Han B, Yang L, Wang X, Zhou G, Zhang T, Li B, Wang Y,
730 Chen Z, Wang X: Neutrophil-to-lymphocyte ratio predicts critical illness patients
731 with 2019 coronavirus disease in the early stage. *J Transl Med* 2020, 18:206.
- 732 37. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, Wang Q, Miao H:
733 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive
734 study. *Signal Transduct Target Ther* 2020, 5:33.
- 735 38. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G,
736 Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y: Reduction and Functional Exhaustion of
737 T Cells in Patients With Coronavirus Disease 2019 (COVID-19). *Front Immunol*
738 2020, 11:827.

739

740

741 **Figure Legends**

742 Figure 1. Body weight change over time and postmortem lung weights. A. Body weight
743 of control mock-inoculated hamsters (shown in blue) compared with SARS-CoV-2
744 inoculated hamsters (red). Mock-inoculated animals demonstrated a steady
745 increase typical of young growing animals. In contrast, SARS-CoV-2 inoculated

746 animals had a sharp decline in body weight until 6 DPI when body weight began to
747 increase. B. At time of necropsy, lung weights of SARS-CoV-2-inoculated (red)
748 hamsters had significantly higher total lung weights at both 4 and 7 DPI ($P= 0.004$,
749 $P= 0.0008$, respectively, unpaired t-test) as compared to mock-inoculated animals,
750 consistent with lesion severity and consolidation.

751 Figure 2. Viral loads throughout the respiratory system. Tissue culture infectious dose
752 50 (TCID₅₀) assay revealed the highest levels of infectious virus present in the nasal
753 turbinates (A), trachea (B), and lungs (C) at 2 DPI. Detectable levels of infectious ARS-
754 CoV-2 were still present in all these tissues at 4 DPI; only a single animal had low level
755 infectious virus at 7 DPI.

756

757 Figure 3. Progressive morphologic alterations in lung over time. Mock-inoculated
758 (intranasal saline alone) animals that served as uninfected controls had no lesions
759 identified by histologic examination. 2DPI: Lung lesions included intraluminal
760 neutrophilic infiltrates and necrotic cellular debris (black arrow), as well as abundant
761 intra-alveolar macrophages, neutrophils, necrotic cellular debris (black asterisk), and
762 fibrinous exudate. 4DPI: Lesions included areas of consolidation consisting of type II
763 pneumocyte hyperplasia, numerous intra-alveolar macrophages, neutrophils, necrotic
764 cellular debris, and eosinophilic fibrinous exudate (black asterisk), and multifocal
765 vasculitis with reactive vascular endothelium (black arrow). 7DPI: Extensive areas of
766 pulmonary consolidation were present (black asterisk) with atypical proliferative type II
767 pneumocyte hyperplasia (black arrow), abundant intra-alveolar macrophages
768 degenerate neutrophils and fewer lymphocytes (black triangle). 14 DPI: There were

769 multiple scattered areas of residual type II pneumocyte hyperplasia (black arrow), with
770 rare clusters of macrophages, lymphocytes, and neutrophils. 28 DPI: Scattered small
771 clusters of type II pneumocyte hyperplasia with cuboidal epithelial cells remained. Top
772 row images at 2x magnification, bottom row 20x magnification, H&E.

773

774 Figure 4: *In situ* hybridization and immunohistochemistry findings in lung. RNAscope *in*
775 *situ* hybridization showed widespread, punctate staining in the lungs within alveolar
776 epithelial cells, alveolar macrophages, bronchial and bronchiolar epithelial cells, and
777 vascular endothelial cells at 2DPI, within alveolar epithelial cells and alveolar
778 macrophages at 4DPI, and in one animal within alveolar epithelial cells at 7DPI. No
779 staining was present at 14DPI (RNAscope *in situ* hybridization with red chromogen and
780 hematoxylin counterstain). Immunostaining to detect Iba-1 revealed that macrophages
781 comprised a major portion of the inflammatory infiltrate beginning at 2DPI and peaking
782 at 7DPI. CD3+ lymphocytes represented a much smaller portion of the inflammatory
783 population in the lungs but also increased from 2-7 DPI then decreased at 14 DPI.
784 (Immunostaining with brown chromogen and hematoxylin counterstain). 20x
785 magnification.

786

787 Figure 5. Consolidation in the lungs comprised of both large numbers of macrophages
788 and extensive type II pneumocyte hyperplasia. A. Representative image of lung at 7DPI
789 showing severe consolidation, including type II pneumocyte hyperplasia with large
790 atypical epithelial cells (white arrows) and multinucleated syncytial cells (black arrow).
791 H&E. B. Similar area of consolidation within the lungs at 7DPI with immunostaining to

792 detect pancytokeratin (red chromogen) and Iba-1 (brown chromogen) revealed that the
793 large, atypical cells and multinucleated cells were epithelial whereas the macrophages
794 were within the alveolar and interstitial spaces. Hematoxylin counterstain, 40X
795 magnification.

796

797 Figure 6. Quantitative digital image analysis of ISH and IHC staining in the lungs using
798 QuPath analysis. A. Quantitation of staining for SARS-CoV-2 RNA within the lungs
799 showed highest levels at 2DPI, with virus still detectable at 4 DPI. No measurable virus
800 was detected at 7 or 14 DPI. B. Copy numbers of viral RNA within the lungs detected by
801 qRT-PCR reached highest levels at 2 and 4 DPI, with progressively lower amounts
802 detected at 7 DPI extending through 28 DPI. C. Quantitation of Iba-1 immunolabeling
803 within the lungs revealed an increase in macrophages in infected animals until 7DPI,
804 with a decrease at 14 DPI, though still above levels found in mock-inoculated animals.
805 D. Quantitation of CD3+ immunolabeling within the lungs revealed an increase in
806 lymphocytes until 4-7DPI. Numbers of lymphocytes were 10-fold lower than
807 macrophages.

808

809 Figure 7. Flow cytometry of whole blood. Whole blood FACS revealed an early
810 decrease in the proportion of circulating CD8+ lymphocytes at 2 DPI (A) while CD4
811 lymphocytes do not differ from baseline (B).

812

813 Supplemental figure 1. Additional images of lung pathology at 7 DPI. A. Many large,
814 atypical cells were present lining the alveolar septa that contained large nuclei with

815 prominent nucleoli and lacy chromatin. B. Frequent multinucleated epithelial cells were
816 present throughout affected areas of lung. C. Numerous mitotic figures were present
817 within areas of type II pneumocyte hyperplasia indicating a robust reparative response.
818 40X magnification, H&E.

819
820 Supplemental figure 2. Pathology of the nasal cavity in SARS-CoV-2-infected hamsters.

821 At 2 and 4 DPI, the nasal cavity of infected animals contained abundant suppurative
822 exudate admixed with proteinaceous material. Inflammatory cells infiltrated into the
823 nasal mucosal epithelium, and there were multiple areas of epithelial erosion and
824 ulceration. A. 2x magnification. B. 20x magnification.

825
826 Supplemental figure 3. Quantitation of consolidation of the lungs at 7 DPI using QuPath.

827 A. Representative image of SARS-CoV-2 infected animal at 7 DPI showing multiple
828 coalescing areas of consolidation. B. Quantitation of affected area using QuPath-
829 generated superpixel classified as either “consolidation” (green), “unaffected” (blue), or
830 “atelectasis” (yellow). Areas where tissue is visible (bronchiolar epithelium, blood
831 vessels), represent superpixels classified as “ignore”. C. Quantitation of consolidated
832 area. Infected animals had significantly higher percentage of tissue consolidation
833 compared to mock animals ($P = 0.0007$, unpaired t-test)

834
835 Supplemental figure 4. *In situ* hybridization of SARS Co-V 2 at 2DPI. SARS CO-V 2
836 RNA (red chromogen) is detectable within the tracheal epithelium (A), bronchial lymph

837 node (B), bronchiolar epithelium (C), and within alveolar epithelial cells and
838 macrophages (D). 40X magnification, hematoxylin counterstain.

839

840 Supplemental QuPath Script Information

841 Note: Annotation of lung sections was performed individually using the “wand” tool.

842 IBA-1 detection and quantification:

843 setImageType('BRIGHTFIELD_H_DAB');

844 setColorDeconvolutionStains({'Name' : "H-DAB default", "Stain 1" : "Hematoxylin",
845 "Values 1" : "0.65111 0.70119 0.29049 ", "Stain 2" : "DAB", "Values 2" : "0.26917
846 0.56824 0.77759 ", "Background" : " 255 255 255 "});

847 addPixelClassifierMeasurements("IBA1_Lung_1", "IBA1_Lung_1")

848

849 CD3 detection and quantification:

850 setImageType('BRIGHTFIELD_H_DAB');

851 setColorDeconvolutionStains({'Name' : "H-DAB default", "Stain 1" : "Hematoxylin",
852 "Values 1" : "0.65111 0.70119 0.29049 ", "Stain 2" : "DAB", "Values 2" : "0.26917
853 0.56824 0.77759 ", "Background" : " 255 255 255 "});

854 selectAnnotations();

855 addPixelClassifierMeasurements("CD3_5", "CD3_5")

856

857 ISH detection and quantification:

858 setImageType('BRIGHTFIELD_H_DAB');

859 setColorDeconvolutionStains({'Name' : "H-DAB default", "Stain 1" : "Hematoxylin",
860 "Values 1" : "0.65111 0.70119 0.29049 ", "Stain 2" : "DAB", "Values 2" : "0.26917
861 0.56824 0.77759 ", "Background" : " 255 255 255 "});

862 selectAnnotations();

863 addPixelClassifierMeasurements("SARS_4", "SARS_4")

864

865 Consolidation:

```
866  setImageType('BRIGHTFIELD_H_E');
867  setColorDeconvolutionStains({'Name' : "H&E default", "Stain 1" : "Hematoxylin",
868  "Values 1" : "0.65111 0.70119 0.29049 ", "Stain 2" : "Eosin", "Values 2" : "0.2159 0.8012
869  0.5581 ", "Background" : " 255 255 255 "});
870  selectAnnotations();
871  runPlugin('qupath.imagej.superpixels.DoGSuperpixelsPlugin', '{"downsampleFactor":
872  8.0, "sigmaMicrons": 5.0, "minThreshold": 15.0, "maxThreshold": 200.0,
873  "noiseThreshold": 0.5}');
874  selectDetections();
875  runPlugin('qupath.lib.algorithms.IntensityFeaturesPlugin', '{"pixelSizeMicrons": 1.0,
876  "region": "ROI", "tileSizeMicrons": 25.0, "colorOD": false, "colorStain1": true,
877  "colorStain2": true, "colorStain3": true, "colorRed": false, "colorGreen": false,
878  "colorBlue": false, "colorHue": false, "colorSaturation": false, "colorBrightness": false,
879  "doMean": true, "doStdDev": false, "doMinMax": true, "doMedian": false, "doHaralick":
880  true, "haralickDistance": 1, "haralickBins": 32}');
881  runObjectClassifier("D7_8");
882
```




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5




Figure 6



A**B**

Figure 7






A**B**



Figure 8




Supplemental Figure 1



Supplemental figure 2.



Supplemental Figure 3.



Supplemental Figure 4